(2R,4S)-N-[2-Chloro-1-[(2S,3S,4R,5S,6S)-3,4,5-Trihydroxy-6-Methylsulfanyl-Tetrahydropyran-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide Hydrochloride

Sterile Dry Powder Filling Under Isolator Conditions: A Monograph-Driven Process

In the manufacture of Lincomycin Hydrochloride for Injectable Powder, the active pharmaceutical ingredient is aseptically processed into final containers without the addition of diluents, flow agents, or preservatives — a direct isolation-to-vial pathway that imposes exceptional demands on crystalline form stability and particulate control. The target fill weight corresponds to 600 mg of lincomycin (base) per 10 mL Type I borosilicate glass vial, which equates to approximately 694 mg of Lincomycin Hydrochloride dihydrate when the potency is adjusted to 865 µg/mg (as-is basis). Regulatory compliance is governed by USP <1> Injections, USP Monograph for Lincomycin Hydrochloride Injection, Ph. Eur. 0018 (Bacterial Endotoxins), and the sterile medicinal product principles of EudraLex Volume 4 Annex 1 and FDA 21 CFR 211.113(b). The API is delivered from micronisation in a barrier isolator accredited to ISO 14644-1 Class 5 (Grade A) with a background of Grade C, following biodecontamination by vaporised hydrogen peroxide; a validated cycle injects 35% w/w hydrogen peroxide solution to sustain a gas-phase concentration of 250–400 ppm for a dwell time of not less than 25 minutes, with aeration to reduce residual H₂O₂ below 1 ppm on vial contact surfaces before filling. The aseptic powder filling station utilises a vacuum‑drum‑auger dosator system or a twin‑screw metering head made from 316L stainless steel with electropolished product contact surfaces (Ra ≤ 0.4 µm). Critical process parameters include auger rotational speed monitored via in‑line 100% checkweighing with a rejection accuracy of ±2 mg, a fill environment maintained at 20–22 °C and relative humidity <30% RH, and oxygen displacement in the headspace through nitrogen flushing to achieve a residual oxygen level of <1.5% (validated by Raman headspace analysis on statistical sampling). Every stoppered and capped vial is subjected to visual inspection and leak testing using high‑voltage leak detection (HVLD) with a sensitivity calibrated to detect defects ≥5 µm. The resulting terminal article is Lincomycin Hydrochloride for Injection, 600 mg/2 mL, reconstituted with Sterile Water for Injection or Bacteriostatic Water for Injection containing 0.9% benzyl alcohol, and is registered as a prescription anti‑infective.

Why Oral Solid Dosage Wet Granulation Often Yields to Direct Compression for Lincomycin Hydrochloride

Lincomycin Hydrochloride dihydrate exhibits moderate hygroscopicity (equilibrium moisture adsorption rising sharply above 60% RH at 25 °C) and a decomposition onset at approximately 152 °C by differential scanning calorimetry, characteristics that shift manufacturing preference toward dry processing routes in capsule and tablet production. A standard immediate‑release capsule dosage form delivers 250 mg lincomycin (base) per unit, using 289 mg Lincomycin Hydrochloride (ca. 68–72% of a size 1 hard gelatin capsule fill weight) combined with a direct‑compression excipient framework of microcrystalline cellulose (NF, grade PH‑102), spray‑dried lactose monohydrate (NF, grade 315) as a brittle‑fracture diluent, croscarmellose sodium (NF, ≤5%) as superdisintegrant, and magnesium stearate (NF, 0.5–0.8% w/w) screened through a 60‑mesh sieve. The powder blend is prepared in a bin blender of 300‑Litre working capacity operating at 12 rpm for 15–20 minutes, with blend uniformity acceptance criteria of content per sample within 90.0–110.0% of label claim and relative standard deviation ≤ 4.0%, per USP <905> post‑validation. Encapsulation is executed on a dosator‑type encapsulator at 60–75% RH‑controlled environment (<40% RH is mandated to prevent powder sticking and gelatin shell embrittlement), with fill weight control limits of ±3.5% on individual capsules and in‑line metal detection. Dissolution testing follows USP <711> Apparatus 2 (paddle, 50 rpm, 900 mL of pH 6.8 phosphate buffer) with a Q value of 80% dissolved in 45 minutes. Where a tabletted form is specified, a rotary press with 13‑mm round flat‑bevel tooling compacts the blend to a target hardness of 6–10 kp and a friability loss <0.8% after 100 revolutions in a Roche friabilator (as per USP <1216>). The finished products — Lincomycin Hydrochloride Capsules 250 mg and Lincomycin Hydrochloride Tablets 500 mg — are packed in HDPE bottles with induction‑sealed closures containing a desiccant canister, and shelf‑life stability is assigned according to zones I–IVa, with photostability verified per .

Manufacture of a topical antibiotic preparation based on Lincomycin Hydrochloride for dermatological and perianal infections routinely employs a hydrophilic or anhydrous ointment base processed in non‑sterile compounding suites that comply with USP <795> Pharmaceutical Compounding — Nonsterile Preparations and 21 CFR 211.28 personnel hygiene requirements. A representative formula targets 2.0% w/w lincomycin (as base), corresponding to 2.30% w/w Lincomycin Hydrochloride dihydrate, dissolved in a small quantity of purified water (USP) before incorporation into a polyethylene glycol ointment base consisting of PEG 400 (45%) and PEG 3350 (53%) thickened with a colloidal silicon dioxide stabiliser (NF) at 0.5%. The vessel used is a planetary vacuum mixer with a bowl capacity of 500 kg, operating under a vacuum of ‑0.08 MPa to de‑aerate the gel‑like matrix; the aqueous API solution is introduced into the molten (60–65 °C) PEG phase under high‑shear agitation at 1500 rpm, followed by slow cooling to 25 °C over 90 minutes under continuous anchor‑stirring at 25 rpm. The resulting translucent ointment is assayed for homogeneity (content uniformity on 10 stratified samples from top, middle, and bottom positions, acceptance criterion 90–110% label claim with RSD ≤ 5.0%), viscosity (25.0–40.0 Pa·s at 25 °C, measured with a helipath T‑bar spindle at 10 rpm), and microbial limits (total aerobic microbial count <100 CFU/g, Staphylococcus aureus and Pseudomonas aeruginosa absent in 1 g, per USP <61> and <62>). The ointment is filled into 15 g and 30 g epoxy‑lined aluminium tubes sealed with a membrane nozzle, and the terminal product is designated Lincomycin Hydrochloride Ointment 2%.

When Lincomycin-Spectinomycin Combination Injection Demands pH-Sensitive API Ratio Balancing

Combined parenteral formulations of Lincomycin Hydrochloride and Spectinomycin Sulfate are widely registered for veterinary use, particularly for the treatment of respiratory and enteric bacterial infections in swine and poultry; the marketed ratio is frequently 50 mg lincomycin (activity) and 100 mg spectinomycin (activity) per mL of aqueous vehicle. Achieving solution stability depends on rigorous adjustment of pH to 4.5–5.0 with dilute hydrochloric acid or sodium hydroxide, because spectinomycin undergoes rapid hydrolytic degradation at pH <3.5 while lincomycin generates the degradation product lincomycin B (via methyl mercaptan elimination) at pH >7.0 and elevated temperatures. The manufacturing process is carried out in Grade C areas with Grade A local protection, and the compounding tank — a jacketed 500 L 316L vessel — is charged with Water for Injection (WFI) at 25±3 °C under nitrogen overlay. The lincomycin hydrochloride is dissolved first at a concentration of 5.8% w/v (equivalent to 50 mg/mL lincomycin base), followed by spectinomycin sulfate tetrahydrate at 14.4% w/v (equivalent to 100 mg/mL spectinomycin base), with each dissolution step requiring 20–30 minutes of low‑shear impeller mixing at 85 rpm. A clarifying and decolourising treatment with activated charcoal (0.1% w/v, pharma‑grade, acid‑washed) is applied for 15 minutes before filtration through a series of 0.45 µm and 0.22 µm PVDF membrane cartridges. Compatibility studies informed by extended design spaces have demonstrated that the ratio of lincomycin to spectinomycin must be controlled within 1:1.95 to 1:2.12 to avoid formation of insoluble spectinomycin‑lincomycin aggregates that appear when spectinomycin excess exceeds 2.15‑fold molar ratio at temperatures below 15 °C. The sterile‑filtered solution is aseptically filled into 100 mL Type II amber glass vials, stoppered with chloro‑butyl rubber closures, and terminally subjected to a light‑obscuration particle count test (USP <788>, limits: ≤ 6000 particles/container at ≥10 µm and ≤ 600 particles/container at ≥25 µm). The final product, Lincomycin‑Spectinomycin Injection, 50 mg/100 mg per mL, is retained in the pharmacopoeial monographs of several jurisdictions (including USP Veterinary Monograph) and carries a defined withdrawal period in food‑producing animals.

Premix Particle Size Distribution Directly Affects In-Vivo Feed Assay Uniformity

Oral administration of lincomycin via medicated feed is authorised in multiple regulatory frameworks — FDA 21 CFR 558.15 sets the approved use level in swine feed at 44–110 g lincomycin per ton of complete feed (Type C), and EU Regulation 1831/2003 establishes the maximum content under category of coccidiostats and antimicrobials — making premix intermediate the critical control point for dose homogeneity. A commercial Lincomycin Hydrochloride Premix is typically manufactured at a concentration of 110 g/kg (as lincomycin base) using a fluid‑energy‑micronised API fraction blended onto a mineral carrier such as calcium carbonate (USP heavy powder, density 1.0–1.2 g/cm³) or refined rice hull meal. The mixing process employs a horizontal double‑ribbon blender of 2000‑Litre gross volume with a working fill of 40–60%, operated at a peripheral ribbon speed of 1.2 m/s; a two‑stage geometric dilution is mandatory — the API is first pre‑blended with 5 kg of carrier in a 50‑Litre V‑shell tumble bin for 10 minutes, then this pre‑mix is added to the main blender and mixed for 15–20 minutes. Homogeneity is verified by collecting 10 stratified thief samples and assaying each for lincomycin content by HPLC according to AOAC 967.43; the acceptance criterion is a coefficient of variation (CV) less than 5.0% and all individual assays within 90–110% of the declared potency. Particle size overlap between the microfine API (D₅₀ 8–12 µm) and the coarse carrier (D₅₀ 150–250 µm) is deliberately minimised to reduce segregation potential during pneumatic conveying, yet the introduction of electrostatic charges during transfer through polyurethane hoses can cause API‑to‑wall adhesion; therefore, in‑line ionising bars generating ±5 kV and a relative humidity maintained above 45% RH in the packaging room are used as mitigation measures. The premix is packed in 25 kg multi‑wall paper bags with an inner polyethylene liner and stored in a dry, ventilated warehouse at 10–30 °C. Where soluble powder formulations are needed for drinking‑water medication, a spray‑dried granulate is produced by dissolving Lincomycin Hydrochloride in WFI along with lactose (NF) as a carrier, spray‑drying in a co‑current tower at an inlet temperature of 180–190 °C and outlet temperature of 85–95 °C to achieve a water content below 0.5% and instant dispersibility; the resulting Lincomycin Hydrochloride Soluble Powder is labelled with a concentration of 40 g/150 g or equivalent, conforming to USP Veterinary Monograph for Lincomycin Soluble Powder.

Multi‑dose ophthalmic preparations containing Lincomycin Hydrochloride are formulated as aqueous, isotonic, preserved solutions for the treatment of bacterial blepharitis and conjunctivitis in human and veterinary practice, with a typical concentration of 0.5% w/v lincomycin base (equivalent to 0.575% w/v Lincomycin Hydrochloride dihydrate). The solution is buffered to pH 6.5–7.0 using monobasic sodium phosphate monohydrate (0.1% w/v) and dibasic sodium phosphate heptahydrate (0.5% w/v) in Water for Injection, and tonicity is adjusted with sodium chloride to 290–310 mOsmol/kg as determined by freezing‑point depression osmometry (USP <785>). Benzalkonium chloride at 0.01% w/v is included as the antimicrobial preservative, its efficacy being challenged against USP <51> required organisms (including Pseudomonas aeruginosa ATCC 9027, Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 8739, Candida albicans ATCC 10231, and Aspergillus brasiliensis ATCC 16404) with acceptance criteria of not less than 1.0‑log reduction for bacteria at 7 days and no increase from 14 to 28 days for fungi. The compounding cascade starts by dissolving the phosphate salts and benzalkonium chloride in 80% of the final volume of WFI at 40 °C, cooling to 25 °C, then adding the accurately weighed Lincomycin Hydrochloride under stirring at 200 rpm until complete dissolution. The bulk solution is filtered through a 0.2 µm polyethersulfone membrane into a sterile hold vessel and subsequently filled under laminar‑flow Grade A in a blow‑fill‑seal (BFS) machine or conventional vial‑filling line into 5 mL or 10 mL low‑density polyethylene dropper bottles. The BFS process parameters — parison temperature 160–180 °C, mould cooling water at 10–12 °C, fill time ≤ 0.8 seconds — are validated to maintain the preservative content within 90–110% of initial specification. The finished product, Lincomycin Hydrochloride Ophthalmic Solution 0.5%, is assigned a shelf life of 24 months when stored at 20–25 °C and should be discarded 28 days after first opening, with a label statement basing on FDA 21 CFR 200.50 ophthalmic package requirements.